SCHEMBL1073157

SCHEMBL1073157

C/C=C/c1ccccc1OC(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.46
PTGES2 Q9H7Z7 1/20 0.46
ALDH1A1 P00352 3/20 0.42
NFE2L2 Q16236 3/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
TFEB P19484 1/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.40
MAPK1 P28482 2/20 0.40
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TRPA1 O75762 1/20 0.40
ACHE P22303 1/20 0.40
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3717231 1.00 AR (0.46) ARPTGES2ALDH1A1NFE2L2IRAK4
SCHEMBL1073158 1.00 AR (0.46) ARPTGES2ALDH1A1NFE2L2IRAK4
SCHEMBL13988354 0.90 AR (0.49) ARPTGES2ALDH1A1NFE2L2IRAK4
SCHEMBL5412728 0.83 ALDH1A1 (0.44) ARPTGES2ALDH1A1NFE2L2IRAK4
SCHEMBL18441111 0.82 L3MBTL1 (0.46) PTGES2ALDH1A1NFE2L2MEN1KMT2A
SCHEMBL28781436 0.81 NFE2L2 (0.65) ARPTGES2NFE2L2TRPA1CYP1A2
SCHEMBL23841293 0.79 AR (0.43) ARPTGES2ALDH1A1NFE2L2IRAK4
SCHEMBL11939336 0.79 KMT2A (0.58) ARNFE2L2TFEBMEN1KMT2A
SCHEMBL14672769 0.79 KDM4E (0.45) ARALDH1A1NFE2L2TFEBMEN1
SCHEMBL2314005 0.79 KDM4E (0.45) ARALDH1A1NFE2L2TFEBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1455937-B1 CHELATING CARBENE LIGAND PRECURSORS AND THEIR USE IN THE SYNTHESIS OF METATHESIS CATALYSTS MATERIA INC (US) 2018-04-11 EP claimed
US-7268242-B2 Contacting a metathesis-active metal carbene complex with an internal olefin ligand precursors followed by crystallization from an organic solvent MATERIA, INC. (US) 2007-09-11 US claimed
US-7026495-B1 Using beta-substituted styrenes instead of terminal olefin compounds such as unsubstituted styrenes to react with a ruthenium complex;recovered and reused; oxidation resistance; storage stability; efficiency; polymerization; cuprous chloride-free and nontoxic; materials handling MATERIA, INC. (US) 2006-04-11 US claimed
US-11794179-B2 Synthesis and characterization of metathesis catalysts UMICORE AG & CO. KG 2023-10-24 US disclosed
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes UMICORE AG & CO. KG (DE) 2023-10-10 US disclosed
EP-4194092-A1 SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS Umicore AG & Co. KG (DE) 2023-06-14 EP disclosed
US-20230172051-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THEREOF LG DISPLAY CO., LTD. (KR) 2023-06-01 US disclosed
US-20220209140-A1 ORGANIC METAL COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND LG DISPLAY CO., LTD. (KR) 2022-06-30 US disclosed
US-20210394167-A1 SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES UMICORE AG & CO. KG (DE) 2021-12-23 US disclosed
US-11192911-B2 Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis APEIRON SYNTHESIS S.A. (PL) 2021-12-07 US disclosed
US-11123722-B2 Synthesis and characterization of Ru alkylidene complexes UMICORE AG & CO. KG 2021-09-21 US disclosed
US-7268242-B2 Contacting a metathesis-active metal carbene complex with an internal olefin ligand precursors followed by crystallization from an organic solvent MATERIA, INC. (US) 2007-09-11 US disclosed
WO-2007075427-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS MATERIA, INC. (US) 2007-07-05 WO disclosed
US-20060122412-A1 Contacting a metathesis-active metal carbene complex with an internal olefin ligand precursors followed by crystallization from an organic solvent MATERIA, INC. (US) 2006-06-08 US disclosed
US-7026495-B1 Using beta-substituted styrenes instead of terminal olefin compounds such as unsubstituted styrenes to react with a ruthenium complex;recovered and reused; oxidation resistance; storage stability; efficiency; polymerization; cuprous chloride-free and nontoxic; materials handling MATERIA, INC. (US) 2006-04-11 US disclosed
EP-1455937-A4 CHELATING CARBENE LIGAND PRECURSORS AND THEIR USE IN THE SYNTHESIS OF METATHESIS CATALYSTS MATERIA INC (US) 2005-10-19 EP disclosed
EP-1455937-A2 CHELATING CARBENE LIGAND PRECURSORS AND THEIR USE IN THE SYNTHESIS OF METATHESIS CATALYSTS Materia, Inc. (US) 2004-09-15 EP disclosed
US-6620955-B1 Complexing group VIII compounds with beta-substituted styrenes, to form stereospecific coordination catalysts used in metathesis ring-opening polymerizations UMICORE AG & CO. KG (DE) 2003-09-16 US disclosed
US-20030166955-A1 Polymerization catalyst for alpha-olefins UMICORE AG & CO. KG (DE) 2003-09-04 US disclosed
WO-2003044060-A2 CHELATING CARBENE LIGAND PRECURSORS AND THEIR USE IN THE SYNTHESIS OF METATHESIS CATALYSTS MATERIA, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122412-A1 Contacting a metathesis-active metal carbene complex with an internal olefin ligand precursors followed by crystallization from an organic solvent HAO2, SCO2, SOD1 AR 2167/4885PTGES2 1093/4885ALDH1A1 987/4885
US-11192911-B2 Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis POR, CYP1B1, CYP4F11 AR 3045/4885PTGES2 879/4885ALDH1A1 406/4885
US-20210394167-A1 SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES PORCN, ORC3, COASY AR 1468/4885PTGES2 348/4885ALDH1A1 1478/4885
US-20220209140-A1 ORGANIC METAL COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND OCIAD1, OLA1, OXA1L AR 2028/4885PTGES2 2748/4885ALDH1A1 196/4885
US-20030166955-A1 Polymerization catalyst for alpha-olefins SOD1, HAO2, SCO2 AR 2380/4885PTGES2 1115/4885ALDH1A1 481/4885
US-11794179-B2 Synthesis and characterization of metathesis catalysts SQLE, FDFT1, FASN AR 2645/4885PTGES2 117/4885ALDH1A1 1128/4885
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes PORCN, ORC3, COASY AR 1468/4885PTGES2 348/4885ALDH1A1 1478/4885
US-11123722-B2 Synthesis and characterization of Ru alkylidene complexes PORCN, ORC3, COASY AR 1468/4885PTGES2 348/4885ALDH1A1 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.